5Antonio R. Inventing the pharmacogenomics business . Am J Health Syst Pharm, 1999, 56 (1) : 40.
6Collins FS. Genetics: an explosion of knowledge is transforming clinical practice. Geriatrics, 1999,54( 1 ) :41.
7Sim E, Payton M, Noble M, et al. An update on genetic, structural and functional studies of arylamine N - acetyltransferases in euearyotes and procaryotes J. Hum Mol Genet, 2000, 9 ( 16 ) :2435.
8March R. Pharmacogenomics: the genomics of drug response.Yeast, 2000. 17 (1) : 16.
9Hamet P. Genes and hypertension: where we are and where we should do. Clin Exp Hypertens, 1999,21(5 -6) : 947.
10Novelli G, Margiord K, Sangiuolo F, et al. Pharmacogenetics of human andraogens and prostatic diseases. Pharmacogcnomics,2001,2(1) :65.
二级参考文献20
1Vatsis K P,Weber W W.Structural heterogeneity of Caucasian N-acetyltransferase at the NAT1 locus[J].Arch Biochem Biophys,1993,301:71-76.
2Ratain M J,Mick R,Berezin F,et al.Paradoxical relationship between acetylator phenotype and amonafide toxicity[J].Clin Pharmacol Ther,1991,50:573-579.
3Spear B B,Heath-Chiozzi M,Huff J.Clinical application of pharmacogenetics[J].Trends in Molecular Mdeicine,2001,5:201-204.
4Lazarou J,Pomeranz B H,Corey P N.Incidence of adverse drug reactionss in hospitalized patients:a meta-analysis of prospective studies[J].J Am MedAssoc,1998,279:1200-1205.
5Norton R M.Clinical pharmacogenomics:application in pharmaceutical R & D[J].Drug Discovery Today,2001,6(4):180-185.
6Evans W E,Reling M V.Pharmacogenomics:translating functional genomics into rational therapeutics[J].Science,286:487-491.
7Eiselt R,Domanski T L,Zibat A,et al.Identification and functional characterization of eight CYP3A4 protein variants[J].Pharmacogenetics,2001,11(5):447-458.
8Sata F,Sapone A,Elizondo G,et al.CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12:00 evidence for an allelic variant with altered catalytic activity[J].Clin Pharmacol Ther,2000,67(1):48-56.
9Rebbeck T R,et al.Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4[J].J Natl Cancer Inst,1998,9:1225-1229.
10Walker A H,et al.Characterization of an allelic variant in the nifedipine-specific element of cyp3a4:ethnic distribution and implications for prostate cancer risk[J].Hum Mutat,1998,12:289-293.
